🌿 Folk Prescriptions

In recent decades, with deeper research into cardiovascular and cerebrovascular diseases, the relationship between endothelial function and these diseases has attracted significant attention. Endothelial dysfunction is the initiating factor of atherosclerosis and the target organ for risk factors in cardiovascular and cerebrovascular diseases. Thus, protecting endothelial function has become a key goal in treating these conditions. Recently, the China Integrative Medicine Association and Yiling Pharmaceutical Group jointly hosted the Academic Symposium on New Progress in Endothelial Dysfunction, where over 600 experts and scholars from the capital region discussed the relationship between endothelial function and cardiovascular/cerebrovascular diseases.
Professor Xu Chengbin from Peking University People’s Hospital pointed out that endothelial cell injury can be triggered by physical, chemical, and biological factors, leading to increased permeability, loss of anticoagulant activity, and decreased nitric oxide (NO). Hypertension, dyslipidemia, diabetes, and smoking can all cause endothelial dysfunction. Professor Zeng Dingyi from the First Affiliated Hospital of China Medical University reported experimental findings showing that Tongxinluo Capsule inhibits neointimal proliferation and vascular remodeling after rabbit vascular angioplasty, reduces plasma ET levels, increases NO, and promotes release of I-PA, thereby correcting endothelial dysfunction.
Professor Yang Yuejin from Fuwai Cardiovascular Hospital, Chinese Academy of Medical Sciences, emphasized that maintaining integrity of myocardial microvessels and preventing reperfusion injury has become critical in the current era of reperfusion therapy. To date, no specific drug has been found. Their experiments revealed that Tongxinluo Capsule significantly increases serum NO levels during late-stage reperfusion after acute myocardial infarction (AMI), lowers plasma ET levels, reduces circulating endothelial cell (CEC) count, and decreases myocardial infarct size. Notably, it outperformed other medications in increasing serum NO and reducing CEC counts, indicating that Tongxinluo protects endothelial cells and alleviates reperfusion injury. Thus, Tongxinluo may serve as a protective agent for microvessels and myocardium in AMI reperfusion therapy.
Professor Hu Changlin from the Department of Neurology, Second Affiliated Hospital of Chongqing Medical University reported that carotid atherosclerosis is one of the major risk factors for cerebrovascular disease. Preliminary observations indicate a 63% incidence rate among cerebrovascular patients. Currently, the prevalence of carotid atherosclerosis in China is increasing. Research shows that after three months of Tongxinluo treatment, patients exhibit significant increases in peak systolic, diastolic, and mean blood flow velocities in the carotid artery, as well as cerebral blood flow, while resistance index decreases. Intima-media thickness significantly reduces (statistically significant compared to pre-treatment), markedly improving clinical symptoms in patients with cerebral ischemia. Carotid plaques also shrink to some extent. During treatment, 30 patients experienced relief from dizziness, headache, and gait instability, with no recurrence observed.